Up-regulation of beta-chemokines and down-modulation of CCR5 co-receptors inhibit simian immunodeficiency virus transmission in non-human primates

Immunology. 2000 Apr;99(4):569-77. doi: 10.1046/j.1365-2567.2000.00993.x.

Abstract

A non-cognate mechanism of protection against human immunodeficiency virus-1 (HIV-1) infection involves up-regulation of beta-chemokines, which bind and may down-modulate the CCR5 co-receptors, thereby preventing transmission of M-tropic HIV-1. The objective of this investigation was to evaluate this mechanism in vivo in non-human primates. Rhesus macaques were immunized by a modified targeted lymph nodes (TLN) route with recombinant simian immunodeficiency virus (SIV) glycoprotein 120 (gp120) and p27 in alum, and adsorbed recombinant granulocyte-macrophage colony-stimulating factor (GM-CSF) with either interleukin (IL)-2 or IL-4. Immunization induced significant increases in the concentrations of CD8 cell-derived suppressor factor (CD8-SF), regulated on activation normal T cells expressed and secreted (RANTES), macrophage inflammatory protein (MIP)-1alpha and MIP-1beta, and down-modulation of the proportion of cells expressing CCR5 (r = 0.737, P<0.05). The macaques were then challenged with SIVmac 220 by the rectal mucosal route. The plasma SIVmac RNA showed a significant inverse correlation with the CD8-SF or the concentration of the three beta-chemokines (r = 0.831 and 0.824, P<0.01), but a positive correlation between the proportion of CCR5+ cells and SIVmac RNA (r = 0.613, P = 0.05). These results demonstrate for the first time in vivo that immunization up-regulates beta-chemokines, which may down-modulate CCR5 co-receptors, and both functions are significantly correlated with the viral load. Hence, the non-cognate beta-chemokine-CCR5 mechanism should be considered as complementary to specific immunity in vaccination against HIV.

Publication types

  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Animals
  • CD8 Antigens / metabolism
  • Chemokine CCL3
  • Chemokine CCL4
  • Chemokine CCL5 / metabolism
  • Chemokines, CC / metabolism*
  • Gene Products, env / genetics
  • Gene Products, gag / administration & dosage
  • Granulocyte-Macrophage Colony-Stimulating Factor / therapeutic use
  • Groin
  • HIV Envelope Protein gp120 / administration & dosage
  • Injections, Subcutaneous
  • Interleukin-2 / therapeutic use
  • Interleukin-4 / therapeutic use
  • Macaca mulatta
  • Macrophage Inflammatory Proteins / metabolism
  • Membrane Glycoproteins*
  • Mucous Membrane / immunology
  • RNA / analysis
  • Receptors, CCR5 / metabolism*
  • Recombinant Proteins
  • Rectum
  • Retroviridae Proteins, Oncogenic / genetics
  • Simian Acquired Immunodeficiency Syndrome / prevention & control*
  • Simian Acquired Immunodeficiency Syndrome / virology
  • Simian Immunodeficiency Virus*
  • Viral Envelope Proteins*
  • Viral Fusion Proteins / genetics
  • Viral Load
  • Viral Vaccines / administration & dosage

Substances

  • CD8 Antigens
  • Chemokine CCL3
  • Chemokine CCL4
  • Chemokine CCL5
  • Chemokines, CC
  • Gag protein p27, Simian immunodeficiency virus
  • Gene Products, env
  • Gene Products, gag
  • HIV Envelope Protein gp120
  • Interleukin-2
  • Macrophage Inflammatory Proteins
  • Membrane Glycoproteins
  • Receptors, CCR5
  • Recombinant Proteins
  • Retroviridae Proteins, Oncogenic
  • Viral Envelope Proteins
  • Viral Fusion Proteins
  • Viral Vaccines
  • gp120 protein, Simian immunodeficiency virus
  • transmembrane protein, Simian immunodeficiency virus
  • Interleukin-4
  • RNA
  • Granulocyte-Macrophage Colony-Stimulating Factor